» Articles » PMID: 37336873

Multi-dimensional Single-cell Characterization Revealed Suppressive Immune Microenvironment in AFP-positive Hepatocellular Carcinoma

Overview
Journal Cell Discov
Date 2023 Jun 19
PMID 37336873
Authors
Affiliations
Soon will be listed here.
Abstract

Alpha-fetoprotein (AFP)-secreting hepatocellular carcinoma (HCC), which accounts for ~75% of HCCs, is more aggressive with a worse prognosis than those without AFP production. The mechanism through which the interaction between tumors and the microenvironment leads to distinct phenotypes is not yet clear. Therefore, our study aims to identify the characteristic features and potential treatment targets of AFP-negative HCC (ANHC) and AFP-positive HCC (APHC). We utilized single-cell RNA sequencing to analyze 6 ANHC, 6 APHC, and 4 adjacent normal tissues. Integrated multi-omics analysis together with survival analysis were also performed. Further validation was conducted via cytometry time-of-flight on 30 HCCs and multiplex immunohistochemistry on additional 59 HCCs. Our data showed that the genes related to antigen processing and interferon-γ response were abundant in tumor cells of APHC. Meanwhile, APHC was associated with multifaceted immune distortion, including exhaustion of diverse T cell subpopulations, and the accumulation of tumor-associated macrophages (TAMs). Notably, TAM-SPP1 was highly enriched in APHC, as was its receptor CD44 on T cells and tumor cells. Targeting the Spp1-Cd44 axis restored T cell function in vitro and significantly reduced tumor burden when treated with either anti-Spp1 or anti-Cd44 antibody alone or in combination with anti-Pd-1 antibody in the mouse model. Furthermore, elevated IL6 and TGF-β1 signaling contributed to the enrichment of TAM-SPP1 in APHC. In conclusion, this study uncovered a highly suppressive microenvironment in APHC and highlighted the role of TAM-SPP1 in regulating the immune microenvironment, thereby revealing the SPP1-CD44 axis as a promising target for achieving a more favorable immune response in APHC treatment.

Citing Articles

Advances and applications in single-cell and spatial genomics.

Wang J, Ye F, Chai H, Jiang Y, Wang T, Ran X Sci China Life Sci. 2025; .

PMID: 39792333 DOI: 10.1007/s11427-024-2770-x.


Identification of a novel subtype of SPP1 + macrophages expressing SIRPα: implications for tumor immune evasion and treatment response prediction.

Chen K, Li Y, Ni J, Yang X, Zhou Y, Pang Y Exp Hematol Oncol. 2024; 13(1):119.

PMID: 39696410 PMC: 11657677. DOI: 10.1186/s40164-024-00587-3.


AFP shields hepatocellular carcinoma from macrophage phagocytosis by regulating HuR-mediated CD47 translocation in cellular membrane.

Pan Y, Yin Q, Wang Z, Wu G, Liu K, Li X Transl Oncol. 2024; 52():102240.

PMID: 39667226 PMC: 11699289. DOI: 10.1016/j.tranon.2024.102240.


scRNA-Seq Analysis Revealed CAFs Regulating HCC Cells via PTN Signaling.

Lin W, Tang L, Zhuo C, Mao X, Shen J, Huang S J Hepatocell Carcinoma. 2024; 11:2269-2281.

PMID: 39582814 PMC: 11583788. DOI: 10.2147/JHC.S493675.


The AFCRPLITY score for predicting the prognosis of immunotherapy combined with local-regional therapy in unresectable hepatocellular carcinoma.

Zuo M, Wei R, Li D, Li W, An C Ther Adv Med Oncol. 2024; 16:17588359241297080.

PMID: 39563715 PMC: 11574904. DOI: 10.1177/17588359241297080.


References
1.
Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

2.
Uehara T, Pogribny I, Rusyn I . The DEN and CCl -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma. Curr Protoc. 2021; 1(8):e211. PMC: 8744072. DOI: 10.1002/cpz1.211. View

3.
Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y . A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021; 184(3):792-809.e23. DOI: 10.1016/j.cell.2021.01.010. View

4.
Browaeys R, Saelens W, Saeys Y . NicheNet: modeling intercellular communication by linking ligands to target genes. Nat Methods. 2019; 17(2):159-162. DOI: 10.1038/s41592-019-0667-5. View

5.
Bader J, Voss K, Rathmell J . Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020; 78(6):1019-1033. PMC: 7339967. DOI: 10.1016/j.molcel.2020.05.034. View